{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:42:00Z","timestamp":1789990920184,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T00:00:00Z","timestamp":1494979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00415-017-8514-z","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T05:43:25Z","timestamp":1494999805000},"page":"1193-1203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis"],"prefix":"10.1007","volume":"264","author":[{"given":"Isabell","family":"Cordts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bodart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathi","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Karagiorgou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Tzartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Rivner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Vigneron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg B.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates J.","family":"Tzartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl G.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,17]]},"reference":[{"key":"8514_CR1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/WCO.0b013e32833cc968","volume":"23","author":"ME Farrugia","year":"2010","unstructured":"Farrugia ME, Vincent A (2010) Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 23:489\u2013495","journal-title":"Curr Opin Neurol"},{"key":"8514_CR2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26:1054\u20131059","journal-title":"Neurology"},{"key":"8514_CR3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368","journal-title":"Nat Med"},{"key":"8514_CR4","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126:2304\u20132311","journal-title":"Brain"},{"key":"8514_CR5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0092-8674(00)81251-9","volume":"85","author":"TM DeChiara","year":"1996","unstructured":"DeChiara TM, Bowen DC, Valenzuela DM, Simmons MV, Poueymirou WT, Thomas S, Kinetz E, Compton DL, Rojas E, Park JS, Smith C, DiStefano PS, Glass DJ, Burden SJ, Yancopoulos GD (1996) The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85:501\u2013512","journal-title":"Cell"},{"key":"8514_CR6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","volume":"135","author":"N Kim","year":"2008","unstructured":"Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, Hubbard SR, Dustin ML, Burden SJ (2008) Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135:334\u2013342","journal-title":"Cell"},{"key":"8514_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1101\/gad.180885.111","volume":"26","author":"Y Zong","year":"2012","unstructured":"Zong Y, Zhang B, Gu S, Lee K, Zhou J, Yao G, Figueiredo D, Perry K, Mei L, Jin R (2012) Structural basis of agrin-LRP4-MuSK signaling. Genes Dev 26:247\u2013258","journal-title":"Genes Dev"},{"key":"8514_CR8","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1172\/JCI66039","volume":"123","author":"C Shen","year":"2013","unstructured":"Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, Jung J, Wu H, Barik A, Yin DM, Xiong WC, Mei L (2013) Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 123:5190\u20135202","journal-title":"J Clin Invest"},{"key":"8514_CR9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69:418\u2013422","journal-title":"Ann Neurol"},{"key":"8514_CR10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Frenkian Cuvelier M, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139\u2013145","journal-title":"J Autoimmun"},{"key":"8514_CR11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","volume":"69","author":"B Zhang","year":"2012","unstructured":"Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, Xiong WC, Lisak RP, Tzartos SJ, Mei L (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69:445\u2013451","journal-title":"Arch Neurol"},{"key":"8514_CR12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","volume":"259","author":"A Pevzner","year":"2012","unstructured":"Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke B, Melms A, Kroger S (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259:427\u2013435","journal-title":"J Neurol"},{"key":"8514_CR13","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","volume":"82","author":"C Gasperi","year":"2014","unstructured":"Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, Risson V, Schaeffer L, Schalke B, Kr\u00f6ger S (2014) Anti-agrin autoantibodies in myasthenia gravis. Neurology 82:1976\u20131983","journal-title":"Neurology"},{"key":"8514_CR14","doi-asserted-by":"crossref","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","volume":"9","author":"B Zhang","year":"2014","unstructured":"Zhang B, Shen C, Bealmear B, Ragheb S, Xiong WC, Lewis RA, Lisak RP, Mei L (2014) Autoantibodies to agrin in myasthenia gravis patients. PLoS One 9:e91816","journal-title":"PLoS One"},{"key":"8514_CR15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","volume":"1275","author":"J Cossins","year":"2012","unstructured":"Cossins J, Belaya K, Zoltowska K, Koneczny I, Maxwell S, Jacobson L, Leite MI, Waters P, Vincent A, Beeson D (2012) The search for new antigenic targets in myasthenia gravis. Ann NY Acad Sci 1275:123\u2013128","journal-title":"Ann NY Acad Sci"},{"key":"8514_CR16","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131:1940\u20131952","journal-title":"Brain"},{"key":"8514_CR17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","volume":"69","author":"S Jacob","year":"2012","unstructured":"Jacob S, Viegas S, Leite MI, Webster R, Cossins J, Kennett R, Hilton-Jones D, Morgan BP, Vincent A (2012) Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 69:994\u20131001","journal-title":"Arch Neurol"},{"key":"8514_CR18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","volume":"284","author":"AI Tsonis","year":"2015","unstructured":"Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Casasnovas Pons C, Pitha J, Jakub\u00edkova M, Hanisch F, Tzartos SJ (2015) MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2014a multinational study. J Neuroimmunol 284:10\u201317","journal-title":"J Neuroimmunol"},{"key":"8514_CR19","first-page":"740583","volume":"2011","author":"S Suzuki","year":"2011","unstructured":"Suzuki S, Utsugisawa K, Nagane Y, Suzuki N (2011) Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011:740583","journal-title":"Autoimmune Dis"},{"key":"8514_CR20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","volume":"13","author":"E Gallardo","year":"2014","unstructured":"Gallardo E, Martinez-Hernandez E, Titulaer MJ, Huijbers MG, Martinez MA, Ramos A, Querol L, Diaz-Manera J, Rojas-Garcia R, Hayworth CR, Verschuuren JJ, Balice-Gordon R, Dalmau J, Illa I (2014) Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 13:1003\u20131007","journal-title":"Autoimmun Rev"},{"key":"8514_CR21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","volume":"73","author":"E Cortes-Vicente","year":"2016","unstructured":"Cortes-Vicente E, Gallardo E, Martinez MA, Diaz-Manera J, Querol L, Rojas-Garcia R, Illa I (2016) Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol 73:1099\u20131104","journal-title":"JAMA Neurol"},{"key":"8514_CR22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","volume":"22","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Nacu A, Andersen JB, Owe JF (2015) Myasthenia gravis and risks for comorbidity. Eur J Neurol 22:17\u201323","journal-title":"Eur J Neurol"},{"key":"8514_CR23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1196\/annals.1405.040","volume":"1132","author":"JA Aarli","year":"2008","unstructured":"Aarli JA (2008) Myasthenia gravis in the elderly. Ann NY Acad Sci 1132:238\u2013243","journal-title":"Ann NY Acad Sci"},{"key":"8514_CR24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Ann Thorac Surg 70:327\u2013334","journal-title":"Ann Thorac Surg"},{"key":"8514_CR25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","volume":"11","author":"SM Hayter","year":"2012","unstructured":"Hayter SM, Cook MC (2012) Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 11:754\u2013765","journal-title":"Autoimmun Rev"},{"key":"8514_CR26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","volume":"74","author":"L Gill","year":"2016","unstructured":"Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I (2016) Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol 74:295\u2013302","journal-title":"J Am Acad Dermatol"},{"key":"8514_CR27","volume-title":"Beck depression inventory-II","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK (1996) Beck depression inventory-II. Psychological Corporation:b9, San Antonio"},{"key":"8514_CR28","volume-title":"Psychotherapie im Dialog-Diagnostik und Evaluation","author":"V K\u00f6llner","year":"2012","unstructured":"K\u00f6llner V, Schauenburg H (2012) Psychotherapie im Dialog-Diagnostik und Evaluation. Georg Thieme Verlag"},{"key":"8514_CR29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","volume":"292","author":"C Stergiou","year":"2016","unstructured":"Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Gilhus NE, Casasnovas Pons C, Pitha J, Jakubikova M, Hanisch F, Bogomolovas J, Labeit D, Labeit S, Tzartos SJ (2016) Titin antibodies in \u201cseronegative\u201d myasthenia gravis - A new role for an old antigen. J Neuroimmunol 292:108\u2013115","journal-title":"J Neuroimmunol"},{"key":"8514_CR30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3109\/08916934.2015.1064400","volume":"48","author":"M Keijzers","year":"2015","unstructured":"Keijzers M, Damoiseaux J, Vigneron A, Bodart N, Kessels A, Dingemans AM, Hochstenbag M, Maessen J, De Baets M (2015) Do associated auto-antibodies influence the outcome of myasthenia gravis after thymectomy? Autoimmunity 48:552\u2013555","journal-title":"Autoimmunity"},{"key":"8514_CR31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cen3.12173","volume":"6","author":"A Evoli","year":"2015","unstructured":"Evoli A, Iorio R (2015) Characteristics of myasthenia gravis with antibodies to muscle-specific kinase and low-density lipoprotein-related receptor protein 4. Clinical and Experimental Neuroimmunology 6:40\u201348","journal-title":"Clinical and Experimental Neuroimmunology"},{"key":"8514_CR32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/08916939509001933","volume":"20","author":"GO Skeie","year":"1995","unstructured":"Skeie GO, Mygland A, Aarli JA, Gilhus NE (1995) Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 20:99\u2013104","journal-title":"Autoimmunity"},{"key":"8514_CR33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ane.12271","volume":"130","author":"P Szczudlik","year":"2014","unstructured":"Szczudlik P, Szyluk B, Lipowska M, Ryniewicz B, Kubiszewska J, Dutkiewicz M, Gilhus NE, Kostera-Pruszczyk A (2014) Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand 130:229\u2013233","journal-title":"Acta Neurol Scand"},{"key":"8514_CR34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archneur.58.6.885","volume":"58","author":"AM Yamamoto","year":"2001","unstructured":"Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez L, Bourquin C, Bach JF, Garchon HJ (2001) Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 58:885\u2013890","journal-title":"Arch Neurol"},{"key":"8514_CR35","first-page":"1006","volume":"251","author":"XJ Chen","year":"2004","unstructured":"Chen XJ, Qiao J, Xiao BG, Lu CZ (2004) The significance of titin antibodies in myasthenia gravis\u2013correlation with thymoma and severity of myasthenia gravis. J Neurol 251:1006\u20131011","journal-title":"J Neurol"},{"key":"8514_CR36","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1212\/WNL.43.8.1581","volume":"43","author":"M Gautel","year":"1993","unstructured":"Gautel M, Lakey A, Barlow DP, Holmes Z, Scales S, Leonard K, Labeit S, Mygland A, Gilhus NE, Aarli JA (1993) Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 43:1581\u20131585","journal-title":"Neurology"},{"key":"8514_CR37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1212\/WNL.59.1.92","volume":"59","author":"FE Somnier","year":"2002","unstructured":"Somnier FE, Engel PJ (2002) The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999. Neurology 59:92\u201398","journal-title":"Neurology"},{"key":"8514_CR38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s004150050604","volume":"247","author":"F Romi","year":"2000","unstructured":"Romi F, Skeie GO, Aarli JA, Gilhus NE (2000) Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 247:369\u2013375","journal-title":"J Neurol"},{"key":"8514_CR39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. The Lancet Neurology 8:475\u2013490","journal-title":"The Lancet Neurology"},{"key":"8514_CR40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0960-8966(96)00009-0","volume":"6","author":"A Evoli","year":"1996","unstructured":"Evoli A, Batocchi AP, Lo Monaco M, Servidei S, Padua L, Majolini L, Tonali P (1996) Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord 6:155\u2013161","journal-title":"Neuromuscul Disord"},{"key":"8514_CR41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","volume":"2","author":"A Vincent","year":"2003","unstructured":"Vincent A, Bowen J, Newsom-Davis J, McConville J (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2:99\u2013106","journal-title":"Lancet Neurol"},{"key":"8514_CR42","doi-asserted-by":"crossref","first-page":"10193","DOI":"10.1038\/srep10193","volume":"5","author":"G Zhao","year":"2015","unstructured":"Zhao G, Wang X, Yu X, Zhang X, Guan Y, Jiang J (2015) Clinical application of clustered-AChR for the detection of SNMG. Sci Rep 5:10193","journal-title":"Sci Rep"},{"key":"8514_CR43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ene.12270","volume":"21","author":"P Devic","year":"2014","unstructured":"Devic P, Petiot P, Simonet T, Stojkovic T, Delmont E, Franques J, Magot A, Vial C, Lagrange E, Nicot AS, Risson V, Eymard B, Schaeffer L (2014) Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur J Neurol 21:130\u2013134","journal-title":"Eur J Neurol"},{"key":"8514_CR44","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","volume":"72","author":"PM Rodriguez Cruz","year":"2015","unstructured":"Rodriguez Cruz PM, Al-Hajjar M, Huda S, Jacobson L, Woodhall M, Jayawant S, Buckley C, Hilton-Jones D, Beeson D, Vincent A, Leite MI, Palace J (2015) Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative Myasthenia Gravis. JAMA Neurol 72:642\u2013649","journal-title":"JAMA Neurol"},{"key":"8514_CR45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/00207454.2010.539307","volume":"121","author":"ZF Mao","year":"2011","unstructured":"Mao ZF, Yang LX, Mo XA, Qin C, Lai YR, He NY, Li T, Hackett ML (2011) Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci 121:121\u2013129","journal-title":"Int J Neurosci"},{"key":"8514_CR46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1530\/acta.0.1010041","volume":"101","author":"WR Kiessling","year":"1982","unstructured":"Kiessling WR, Finke R, Kotulla P, Schleusener H (1982) Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis. Acta Endocrinol (Copenh) 101:41\u201346","journal-title":"Acta Endocrinol (Copenh)"},{"key":"8514_CR47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0404.2012.01693.x","volume":"127","author":"YL Chen","year":"2013","unstructured":"Chen YL, Yeh JH, Chiu HC (2013) Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol Scand 127:170\u2013174","journal-title":"Acta Neurol Scand"},{"key":"8514_CR48","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1468-1331.2007.01978.x","volume":"14","author":"M Kanazawa","year":"2007","unstructured":"Kanazawa M, Shimohata T, Tanaka K, Nishizawa M (2007) Clinical features of patients with myasthenia gravis associated with autoimmune diseases. Eur J Neurol 14:1403\u20131404","journal-title":"Eur J Neurol"},{"key":"8514_CR49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jnnp.2008.167163","volume":"9","author":"N Mistry","year":"2009","unstructured":"Mistry N, Wass J, Turner MR (2009) When to consider thyroid dysfunction in the neurology clinic. Pract Neurol 9:145\u2013156","journal-title":"Pract Neurol"},{"key":"8514_CR50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-0404.2006.00649.x","volume":"114","author":"C Toth","year":"2006","unstructured":"Toth C, McDonald D, Oger J, Brownell K (2006) Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand 114:124\u2013132","journal-title":"Acta Neurol Scand"},{"key":"8514_CR51","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.humimm.2013.06.020","volume":"74","author":"R Klein","year":"2013","unstructured":"Klein R, Marx A, Strobel P, Schalke B, Nix W, Willcox N (2013) Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum Immunol 74:1184\u20131193","journal-title":"Hum Immunol"},{"key":"8514_CR52","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526\u20131533","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-017-8514-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8514-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8514-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T15:20:14Z","timestamp":1569338414000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-017-8514-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,17]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["8514"],"URL":"https:\/\/doi.org\/10.1007\/s00415-017-8514-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,17]]}}}